அன்னே மருதாணி வேரா லாங் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அன்னே மருதாணி வேரா லாங். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அன்னே மருதாணி வேரா லாங் Today - Breaking & Trending Today

DGAP-News: Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

DGAP-News: Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity
boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.

Anne Hennecke Vera Lang , Planegg Martinsried , Alexander Gebauer , Frank Jaschinski , Secarna Pharmaceuticals Gmbh Co , Mc Services , Secarna Pharmaceuticals , Distribution Services , Secarna Pharmaceuticals Gmbh , Nucleic Acid Therapeutics , Pharmaceuticals Gmbh , Managing Director , Corporate News , Regulatory Announcements , அன்னே மருதாணி வேரா லாங் , அலெக்சாண்டர் கேபோஊெர் , ம்ஸீ சேவைகள் , விநியோகம் சேவைகள் , மருந்துகள் கஂப் , நிர்வகித்தல் இயக்குனர் , பெருநிறுவன செய்தி , ஒழுங்குமுறை அறிவிப்புகள் ,

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG: Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals' LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids

(1)
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG
/ Key word(s): Miscellaneous
Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids
19.01.2021 / 15:00
Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals LNAplus
TM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids
Secarna s partner Lipigon has selected an LNAplus
TM ASO candidate targeting ANGPTL4, called
Lipisense, which has shown unique efficacy in reducing lipid triglycerides in experimental disease models and is now entering pre-clinical safety development
High levels of plasma lipids triglycerides are associated with a plethora of lipid-related diseases with yet unmet clinical treatment needs ....

Anne Hennecke Vera Lang , Stefank Nilsson , Kostenloser Wertpapierhandel , Planegg Martinsried , Jonas Renz , Secarna Pharmaceuticals Gmbh Co , Mc Services , Lipigon Pharmaceuticals , Secarna Pharmaceuticals , Distribution Services , Secarna Pharmaceuticals Gmbh , Secarna Pharmaceutical , Pharmaceuticals Gmbh , Familial Chylomicronemia Syndrome , Managing Director , Corporate News , Regulatory Announcements , அன்னே மருதாணி வேரா லாங் , ஜோனாஸ் ரென்ஸ் , ம்ஸீ சேவைகள் , விநியோகம் சேவைகள் , மருந்துகள் கஂப் , நிர்வகித்தல் இயக்குனர் , பெருநிறுவன செய்தி , ஒழுங்குமுறை அறிவிப்புகள் ,

sterna biologicals GmbH & Co. KG Raises Further EUR 10.0 Million (approx. USD 11.9 million) in Series A

Press release content from Accesswire. The AP news staff was not involved in its creation.
sterna biologicals GmbH & Co. KG Raises Further EUR 10.0 Million (approx. USD 11.9 million) in Series A - 2nd Closing Private Placement
January 7, 2021 GMT
Following successful completion of the company’s Series A - 1st closing with EUR 12.0 million in April 2020, sterna now has successfully completed a 2nd closing with another EUR 10.0 million, bringing the Series A total to EUR 22.0 million
Proceeds from the 2nd closing will fund phase IIb preparatory activities including toxicology studies and CMC work for SB010 in moderate to severe asthma as well as the completion of an oral formulation project for SB012 laying the foundation for phase I/IIb studies in moderate to severe ulcerative colitis ....

Anne Hennecke Vera Lang , Christian Pangratz , Mc Services , Gmbh Co , Chief Executive Officer , New England Journal , அன்னே மருதாணி வேரா லாங் , ம்ஸீ சேவைகள் , கஂப் இணை , தலைமை நிர்வாகி அதிகாரி , புதியது இங்கிலாந்து இதழ் ,

DGAP-News: sterna biologicals GmbH & Co. KG raises further EUR 10.0 million (approx. USD 11.9 million) in Series A

DGAP-News: stern .
DGAP-News: sterna biologicals GmbH & Co. KG raises further EUR 10.0 million (approx. USD 11.9 million) in Series A - 2nd closing private placement
vom 07.01.2021, 15:00 Uhr
Bild: pixabay.com
DGAP-News: sterna biologicals GmbH & Co. KG
/ Key word(s): Financing
sterna biologicals GmbH & Co. KG raises further EUR 10.0 million (approx. USD 11.9 million) in Series A - 2nd closing private placement
07.01.2021 / 15:00
STERNA BIOLOGICALS RAISES FURTHER EUR 10.0 MILLION (APPROX. USD 11.9 MILLION) IN SERIES A - 2
nd CLOSING PRIVATE PLACEMENT
Following successful completion of the company s Series A - 1
st closing with EUR 12.0 million in April 2020, sterna now has successfully completed a 2
nd closing with another EUR 10.0 million, bringing the Series A total to EUR 22.0 million ....

Anne Hennecke Vera Lang , Christian Pangratz , Mc Services , Gmbh Co , Distribution Services , Chief Executive Officer , New England Journal , Corporate News , Regulatory Announcements , அன்னே மருதாணி வேரா லாங் , ம்ஸீ சேவைகள் , கஂப் இணை , விநியோகம் சேவைகள் , தலைமை நிர்வாகி அதிகாரி , புதியது இங்கிலாந்து இதழ் , பெருநிறுவன செய்தி , ஒழுங்குமுறை அறிவிப்புகள் ,